OIPE JC145 JUL 11 2005 PATENT & TRADEMARK OFFICE

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Ian Churcher, et al.		Examiner: Nwaonicha
Serial No.:	10/679,557	Case No.: T1584	
Filing Date:	October 6, 2003		Art Unit: 1624
For:	CYCLOHEXYL SULPHONE DERIVATIVES AS GAMMA SECRETASE INHIBITORS		

Commissioner for Patents
P.O. BOX 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

I hereby certify that this correspondence is being deposited with the United States Postal Services as first class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450, on the date appearing Below.

MERCK & CO., INC.

By _____ Date 7-8-05

07/12/2005 SSITHIB1 00000018 132755 10679557
01 FC:1806 180.00 DA

This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed contemporaneously with a Request for Continued Examination.

Copies of the non-U.S. patent documents that are cited on the attached form PTO-1449 are enclosed herewith.

References "A-F" in the "U.S. Patent Documents" table of the accompanying PTO 1449 form are co-pending, commonly owned published U.S. patent applications. References B-E correspond to published International applications, which are also listed on the accompanying PTO 1449 form. For the Examiner's convenience, the table below lists the corresponding US and PCT publications:

US Publication No.	International Publication No.
US 2004-00116404	WO 02/081435
US 2004-0082617	WO 02/081433
US 2004-0230054	WO 2004/101538
US 2004-0230054	WO 2004/101539
US 2003-0114496	WO 03/018543

English language abstracts are provided for "Foreign Patent Document" reference G (WO 2004/048321), which is in the German language, and references H (WO 2005/000798), L (JP 56 025149), M (JP 56 026866) and N (JP 56 026847), which are in the Japanese language.

Reference I in the "Foreign Patent Documents" table (EP 1 466 898) is an English language equivalent of Japanese language reference WO 03/055850, which was submitted in the Information Disclosure Statement mailed January 23, 2004.

Reference J in the "Foreign Patent Documents" table (CA 2 473 374) is an English language equivalent of German language reference WO 03/059335, which was submitted in the Information Disclosure Statement mailed January 23, 2004.

Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

By _____

John C. Todaro, Reg. No. 36,036
Attorney for Applicant

MERCK & CO., Inc.
P.O. Box 2000
Rahway, New Jersey 07065-0907
(732) 594-0125

Date: July 8, 2005

Approved for use through 7/31/2006. OMB 0651-0031
SUBSTITUTE for PTO/SB/08A (08-03), Information Disclosure Statement by Applicant
Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

OIPE JUL 11 2005 PATENT & TRADEMARK OFFICE

Sheet 1 of 3

COMPLETE IF KNOWN	
Application Number	10/679,557
Filing Date	October 6, 2003
First Named Inventor	Ian Churcher et al.
Group Art Unit	1624
Examiner Name	Nwaonicha
Attorney Docket Number	T1584

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
	A	US 2004/0171683		Castro Pineiro	09/02/2004
	B	US 2004/0116404		Pineiro et al.	06/17/2004
	C	US 2004/0082617		Harrison et al.	04/29/2004
	D	US 2004/0230054		Dinnell et al.	11/18/2004
	E	US 2004/0114496		Sogawa et al.	06/17/2004
	F	US 2005/0075320		Nadin et al.	04/07/2005

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
	A		WO 02/081435		Merck Sharp & Dohme Limited	10/17/2002
	B		WO 02/081433		Merck Sharp & Dohme Limited	10/17/2002
	C		WO 03/018543		Merck Sharp & Dohme Limited	03/06/2003
	D		WO 2004/031138		Merck Sharp & Dohme Limited	04/15/2004
	E		WO 2004/101539		Merck Sharp & Dohme Limited	11/25/2004
	F		WO 2004/101538		Merck Sharp & Dohme Limited	11/25/2004
	G		WO 2004/048321		Bayer Healthcare AG	06/10/2004
	H		WO 2005/000798		Daiichi Pharmaceutical Co., Ltd.	01/06/2005
	I		EP 1 466 898		Daiichi Pharmaceutical Co., Ltd.	10/13/2004

Examiner Signature		Date Considered	

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 7/31/2006. OMB 0651-0031
SUBSTITUTE for PTO/SB/08A (08-03), Information Disclosure Statement by Applicant
Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

COMPLETE IF KNOWN	
Application Number	10/679,557
Filing Date	October 6, 2003
First Named Inventor	Ian Churcher et al.
Group Art Unit	1624
Examiner Name	Nwaonicha
Attorney Docket Number	T1584

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
	J		CA 2 473 374		Bayer Healthcare AG	07/24/2003
	K		WO 2004/013090		Merck Sharp & Dohme Ltd et al	02/12/2004
	L		JP 56025149		Sagami Chemical Research Center	03/10/1981
	M		JP 56026866		Sagami Chemical Research Center	03/16/1981
	N		JP 56026847		Sagami Chemical Research Center	03/16/1981

Examiner Signature		Date Considered	

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 7/31/2006. OMB 0651-0031
* SUBSTITUTE for PTO/SB/08A (08-03), Information Disclosure Statement by Applicant
Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 3

COMPLETE IF KNOWN	
Application Number	10/679,557
Filing Date	October 6, 2003
First Named Inventor	Ian Churcher et al.
Group Art Unit	1624
Examiner Name	Nwaonicha
Attorney Docket Number	T1584

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	1	J. P. Scott et al., "Expedient Diels-Alder assembly of 4-aryl-4-phenylsulfonyl cyclohexanones", Tetrahedron Letters, Vol. 45, pp. 3345-3348 (2004)
	2	E. W. Garbisch et al., "On the Mechanism of Benzylic Substituent Hydrogenolysis", Journal of the American Chemical Society, Vol. 89(16), pp. 4233-4235 (1967)
	3	R. K. Norris et al., "An Example of Substitution proceeding with Retention in the SRN1 Reaction. Trapping of a Pyramidal Benzylic Radical by Benzenethiolate Ion", J. of the Chem. Soc. Chem. Comm., Issue 3, pp. 79-80 (1981)

Examiner Signature		Date Considered	

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form " IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003